摘要
[目的]探讨KIR基因多态性与乙型肝炎病毒(HBV)感染及机体对干扰素抗HBV治疗应答差异的相关性。[方法]于2010年以2005~2008年青岛市传染病医院就诊的乙肝患者160例为病例组(HBV急性自限性感染者60例为急乙肝组、慢性HBV持续性感染者100例为慢乙肝组),从中国造血干细胞志愿捐献者库青岛分库中随机选择健康捐献者100名为对照组,对照组间及其与病例组间均无亲缘关系。慢乙肝组中48例为干扰素治疗完全应答者(应答组),52例为干扰素治疗低应答者或不应答者(无应答组),分别进行KIR基因分型检测并比较其分布情况。[结果]KIR2DS4*001-002的阳性率,慢乙肝组为87.00%,急乙肝组为73.33%,对照组为72.00%(P〈0.05或〈0.01)。慢乙肝组中,KIR 2DS4003-007的阳性率干扰素治疗应答组与无应答组分别为18.75%、55.77%(P〈0.01);3DP*1001/002/004阳性率应答组与非应答组分别为14.58%、0.00%(P〈0.01);2DL5B*002/004/007阳性率应答组与无应答组分别为10.42%、0.00%(P〈0.05)。[结论]KIR 2DS4*001-002可能与HBV感染慢性化有关。KIR 2DS4*003-007可能与干扰素对HBV的无应答有关,3DP*1001/002/004和2DL5B*002/004/007基因可能有助于慢性乙型肝炎患者干扰素治疗的应答。
[Objective]To study the association between the polymorphism of killer cell immunoglobulin-like receptors(KIR) gene and the prognosis of HBV infection and the treatment response of interferon.[Methods]160 hepatitis B patients were enrolled from Qingdao hospital for infectious diseases during 2005-2008 as the patient group,including 60 cases of patients recovered from acute HBV infection as acute hepatitis B group(AHB),100 cases of HBV chronic infection as chronic hepatitis B group(CHB).To select randomly 100 cases of China Marrow Donor Program Qingdao branch HSC donation volunteers as control group.Among CHB group,48 cases responding to interferon therapy were named as responding group,and 52 cases were non-responders to interferon therapy as non-responding group.KIR genotyping test was conducted and the frequencies of KIR gene were compared statistically in all the patient group and control group in 2010.[Results]The frequency of KIR 2DS4*001-002 in CHB,AHB and control group was 87.00%,73.33%,72.00%,respectively(P〈0.05 and P〈0.01).In the CHB group,the frequencies of KIR 2DS4003-007 in responding group and non-responding group were 18.75%,55.77%(P〈0.01),3DP*1001/002/004 were 14.58%,0.00%(P〈0.01),2DL5B*002/004/007 were 10.42%、0.00%(P〈0.05),respectively.[Conclusion]KIR 2DS4*001-002 may be associated with chronic infection of HBV.KIR 2DS4*003,007 is probably associated with non-response to interferon treatment,3DP*1001/002/004 and 2DL5B*002/004/007 may be helpful to the treatment response of interferon in patients of chronic HBV infection.
出处
《预防医学论坛》
2011年第8期675-678,共4页
Preventive Medicine Tribune
基金
青岛市科技发展计划项目(编号:KZzd-72)